Saturday 13 September | 04:18:36 Europe / Stockholm

Calendar

Est. time*
2026-02-25 08:20 Year-end Report 2025
2025-11-06 08:30 Quarterly Report 2025-Q3
2025-08-13 - Quarterly Report 2025-Q2
2025-06-26 - Annual General meeting
2025-05-28 - Quarterly Report 2025-Q1
2025-05-21 - Ex-date Ordinary Dividend PMED 0.00 SEK
2025-02-28 - Year-end Report 2024
2025-01-07 - Extra General Meeting 2024
2024-11-06 - Quarterly Report 2024-Q3
2024-08-15 - Quarterly Report 2024-Q2
2024-05-22 - Ex-date Ordinary Dividend PMED 0.00 SEK
2024-05-21 - Annual General meeting
2024-05-07 - Quarterly Report 2024-Q1
2024-02-23 - Year-end Report 2023
2024-01-11 - Extra General Meeting 2023
2023-10-24 - Quarterly Report 2023-Q3
2023-08-11 - Quarterly Report 2023-Q2
2023-04-24 - Quarterly Report 2023-Q1
2023-04-21 - Ex-date Ordinary Dividend PMED 0.00 SEK
2023-04-20 - Annual General meeting
2023-02-24 - Year-end Report 2022
2023-01-09 - Extra General Meeting 2022
2022-11-10 - Quarterly Report 2022-Q3
2022-08-18 - Quarterly Report 2022-Q2
2022-05-25 - Ex-date Ordinary Dividend PMED 0.00 SEK
2022-05-24 - Annual General meeting
2022-05-12 - Quarterly Report 2022-Q1
2022-02-25 - Year-end Report 2021
2021-12-16 - Extra General Meeting 2021
2021-11-10 - Quarterly Report 2021-Q3
2021-08-18 - Quarterly Report 2021-Q2
2021-06-10 - Ex-date Ordinary Dividend PMED 0.00 SEK
2021-05-27 - Annual General meeting
2021-05-12 - Quarterly Report 2021-Q1
2021-02-26 - Year-end Report 2020
2020-11-10 - Quarterly Report 2020-Q3
2020-08-17 - Quarterly Report 2020-Q2
2020-07-28 - Extra General Meeting 2020
2020-06-30 - Annual General meeting
2020-06-17 - Ex-date Ordinary Dividend PMED 0.00 SEK
2020-05-14 - Quarterly Report 2020-Q1
2020-02-27 - Year-end Report 2019
2019-11-08 - Quarterly Report 2019-Q3
2019-08-16 - Quarterly Report 2019-Q2
2019-06-20 - Ex-date Ordinary Dividend PMED 0.00 SEK
2019-06-19 - Annual General meeting
2019-05-15 - Quarterly Report 2019-Q1
2019-02-27 - Year-end Report 2018
2018-11-09 - Quarterly Report 2018-Q3
2018-08-17 - Quarterly Report 2018-Q2
2018-05-15 - Quarterly Report 2018-Q1
2018-03-29 - Ex-date Ordinary Dividend PMED 0.00 SEK
2018-03-28 - Annual General meeting
2018-02-27 - Year-end Report 2017
2017-11-09 - Quarterly Report 2017-Q3
2017-08-17 - Quarterly Report 2017-Q2
2017-05-19 - Ex-date Ordinary Dividend PMED 0.00 SEK
2017-05-18 - Annual General meeting
2017-05-16 - Quarterly Report 2017-Q1
2017-02-27 - Year-end Report 2016
2016-11-10 - Quarterly Report 2016-Q3
2016-08-17 - Quarterly Report 2016-Q2
2016-07-22 - Extra General Meeting 2016
2016-05-20 - Ex-date Ordinary Dividend PMED 0.00 SEK
2016-05-19 - Annual General meeting
2016-05-17 - Quarterly Report 2016-Q1
2016-02-26 - Year-end Report 2015
2015-11-19 - Extra General Meeting 2015
2015-11-11 - Quarterly Report 2015-Q3
2015-08-17 - Quarterly Report 2015-Q2
2015-05-08 - Quarterly Report 2015-Q1
2015-04-10 - Ex-date Ordinary Dividend PMED 0.00 SEK
2015-04-09 - Annual General meeting
2015-02-27 - Year-end Report 2014
2014-10-15 - Quarterly Report 2014-Q3
2014-08-13 - Quarterly Report 2014-Q2

Description

CountrySweden
ListSpotlight
SectorHealth care
IndustryBiotechnology
Peptonic Medical is a pharmaceutical company. Currently, the focus is on the treatment of female vaginal atrophy. The company offers a treatment free from oestrogen, where the products contain the oxytocin hormone. A large part of the projects is carried out in collaboration with other industry players. The main business is found on the Nordic market. The company is based in Bromma.
2025-04-28 14:35:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.

PEPTONIC medical AB ("Peptonic" or the "Company") announces that the rights issue which the board of directors resolved on November 28, 2024, and was approved at the extra general meeting on January 7, 2025 (the "Rights Issue") has been registered with the Swedish Companies Registration Office (Bolagsverket). Trading of paid subscribed units ("BTU") will therefore cease, and BTU will be replaced by shares. The last day of trading with BTU is May 2, 2025.

In connection with the registration with the Swedish Companies Registration Office, BTU are converted into newly issued shares.

For more information contact:

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.